Combination biomarkers can predict responses to immune checkpoint inhibitors for bladder cancer patients

Researchers at The University of Texas MD Anderson Cancer Center (TX, USA) have identified a novel combination of biomarkers, obtained from baseline tumor tissues, that can predict clinical responses and overall survival (OS) for patients with metastatic bladder cancer following treatment with immune checkpoint inhibitors. The results of the study, published in Science Translational Medicine, could lead to an improvement in patient selection for such therapies by use of these biomarkers. Urothelial cancers are the sixth most common cancer type in the US, while the five-year OS rates for patients with metastatic cancers are approximately 5%. Though immune checkpoint therapy...

To view this content, please register now for access

It's completely free